Product Description
Specifications
|
Appearance:
|
White to beige Powder
|
|
Melting point
|
140 - 160°C
|
|
Solubility
|
Soluble to 29.65 mg/ml in water, DMSO (Slightly), Methanol (Slightly)
|
|
Purity
|
99%
|
|
Storage temp.
|
-15°C
|
AI Product Description
*The following content is generated by AI and is for reference only.
Carbetocin is a synthetic analogue of the endogenous hormone oxytocin, specifically designed for the prevention and treatment of postpartum hemorrhage (PPH). It belongs to the class of uterotonics and functions by binding to oxytocin receptors on the myometrium, inducing strong, sustained uterine contractions that compress blood vessels at the placental site, thereby controlling excessive bleeding after childbirth. Unlike natural oxytocin, which has a very short half-life of approximately three minutes, Carbetocin possesses a modified structure featuring an N-terminal substitution and a D-amino acid at position 8. This structural alteration significantly extends its biological half-life to roughly 40 to 60 minutes, allowing for a single intravenous or intramuscular dose to maintain effective uterine tone for up to four hours without the need for continuous infusion.
The chemical identity of Carbetocin is defined by its molecular formula, C46H71N15O12S2, and it is assigned the CAS Registry Number 9038-16-2. Its primary clinical application is as a first-line agent for PPH prophylaxis in women undergoing cesarean sections or vaginal deliveries where risk factors for hemorrhage are present. The World Health Organization recommends it as a safe and effective alternative to oxytocin due to its ease of administration and prolonged duration of action. Common side effects may include nausea, vomiting, headache, flushing, and transient hypotension, though severe adverse reactions are rare when administered according to guidelines. By providing reliable hemostasis with a single-dose regimen, Carbetocin plays a critical role in reducing maternal mortality rates globally, particularly in settings where continuous monitoring equipment or skilled personnel for managing infusions are limited. Its development represents a significant advancement in obstetric pharmacology, offering a practical solution to one of the leading causes of maternal death worldwide while minimizing the logistical burden on healthcare providers during high-stress delivery scenarios.